Source-grounded facts extracted from Corbus Pharmaceuticals Holdings, Inc.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
Brent Pfeiffenberger was appointed as Director at Corbus Pharmaceuticals Holdings, Inc..
“On May 19, 2026, the Compensation Committee granted Brent Pfeiffenberger the following initial equity awards under the Corbus Pharmaceuticals Holdings, Inc. 2024 Equity Incentive Plan (the “2024 Plan”) in connection with his appointment to the Board”
Corbus Pharmaceuticals Holdings, Inc. shareholders approved Advisory vote on frequency of future advisory votes on executive compensation (every year, two years, or three years) at the 2026-05-13 meeting.
“The votes were cast as follows with respect to the proposal to vote, on an advisory basis, on whether an advisory vote on executive compensation should occur every year, two years or three years. In accordance with the votes, an advisory vote to approve executive compensation will occur every year until the next required vote on the frequency of future advisory votes to approve executive compensation, or until the Company otherwise determines that a different frequency for such advisory votes is in the best interest of the Company: Every Year Every Two Years Every Three Years Abstentions 9,712,048 151,354 198,373 12,295”
Corbus Pharmaceuticals Holdings, Inc. shareholders approved Advisory vote on executive compensation of named executive officers at the 2026-05-13 meeting.
“The proposal to vote, on an advisory basis, on the compensation of the Company’s named executive officers as described in the Company’s definitive proxy statement was approved based upon the following votes: Votes For Votes Against Abstentions Broker Non-Votes 9,325,932 721,442 26,696 4,060,300”
Corbus Pharmaceuticals Holdings, Inc. shareholders approved Ratification of appointment of EisnerAmper LLP as independent registered public accounting firm for fiscal year ending December 31, 2026 at the 2026-05-13 meeting.
“The proposal to ratify the appointment of EisnerAmper LLP as the Company’s independent registered public accounting firm for the Company’s fiscal year ending December 31, 2026, was approved based upon the following votes: Votes For Votes Against Abstentions 14,102,264 14,731 17,375”
Corbus Pharmaceuticals Holdings, Inc. shareholders approved Approval of the 2024 Plan Amendment at the 2026-05-13 meeting.
“The proposal to approve the 2024 Plan Amendment, was approved based on the following votes: Votes For Votes Against Abstentions Broker Non-Votes 5,950,038 4,099,773 24,259 4,060,300”
Corbus Pharmaceuticals Holdings, Inc. shareholders approved Election of each of Yuval Cohen, Rachelle Jacques, John Jenkins, Anne Altmeyer, Yong Ben, and Winston Kung as directors at the 2026-05-13 meeting.
“The election of each of Yuval Cohen, Rachelle Jacques, John Jenkins, Anne Altmeyer, Yong Ben, and Winston Kung as directors to hold office for a term of one year, until his or her successor is duly elected and qualified or he or she is otherwise unable to complete his or her term. The votes were cast for this matter as follows: Nominees Votes For Votes Withheld Broker Non-Votes Yuval Cohen 9,986,956 87,114 4,060,300 Rachelle Jacques 9,647,139 426,931 4,060,300 John Jenkins 9,636,703 437,367 4,060,300 Anne Altmeyer 9,621,769 452,301 4,060,300 Yong Ben 9,988,459 85,611 4,060,300 Winston Kung 9,979,901 94,169 4,060,300”
Brent Pfeiffenberger was appointed as director at Corbus Pharmaceuticals Holdings, Inc..
“On May 13, 2026, the board of directors (the “Board”) of Corbus Pharmaceuticals Holdings, Inc. (the “Company”), upon the recommendation of the Nominating and Corporate Governance Committee of the Board, appointed Brent Pfeiffenberger, age 48, to serve as a member of the Board, thereby expanding the Board to seven members.”
Corbus Pharmaceuticals Holdings, Inc. reported first quarter ended March 31, 2026 results: net income net loss of approximately $23.0 million, EPS net loss per basic and diluted share of $1.23.
“Corbus Pharmaceuticals Reports Q1 2026 Financial Results and Provides a Corporate Update”
Corbus Pharmaceuticals Holdings, Inc. reported fourth quarter and year ended December 31, 2025 results: net income net loss of approximately $20.6 million, or a net loss per basic and diluted share of $1.25, EPS net loss per basic and diluted share of $1.25.
“The Company reported a net loss of approximately $20.6 million, or a net loss per basic and diluted share of $1.25, for the three months ended December 31, 2025, compared to a net loss of $9.5 million, or a net loss per basic and diluted share of $0.78, for the three months ended December 31, 2024.”
Peter Salzmann departed as Director at Corbus Pharmaceuticals Holdings, Inc..
“Dr. Peter Salzmann advised the Board of Directors (the “Board”) of Corbus Pharmaceuticals Holdings, Inc. (the “Company”) that he will not stand for re-election as a director of the Company at the 2025 annual meeting of stockholders (the “2025 Annual Meeting”).”
Ian Hodgson was appointed as Chief Operating Officer at Corbus Pharmaceuticals Holdings, Inc..
“On March 13, 2025, the Board of Directors (the “Board”) of Corbus Pharmaceuticals Holdings, Inc. (the “Company”) appointed Ian Hodgson as Chief Operating Officer effective March 15, 2025.”
Winston W. Kung was appointed as Director at Corbus Pharmaceuticals Holdings, Inc..
“Effective August 16, 2024, the Board, upon the recommendation of the Nominating and Corporate Governance Committee of the Board, appointed Winston W. Kung, age 49, to serve as a member of the Board.”
Avery W. Catlin resigned as Director at Corbus Pharmaceuticals Holdings, Inc..
“On August 15, 2024, Avery W. Catlin submitted his resignation from the Board of Directors (the “Board”) of Corbus Pharmaceuticals Holdings, Inc. (the “Company”), effective as of August 15, 2024.”
Corbus Pharmaceuticals Holdings, Inc. reported the three months ended March 31, 2024 results: net income approximately $6.9 million, EPS a net loss per diluted share of $0.83.
“The Company reported a net loss of approximately $6.9 million, or a net loss per diluted share of $0.83, for the three months ended March 31, 2024, compared to a net loss of approximately $17.7 million, or a net loss per diluted share of $4.24, for the same period in 2023.”
Corbus Pharmaceuticals Holdings, Inc. reported the fourth quarter of 2023 and year-ended 2023 results: net income the Company reported a net loss of approximately $8.0 million, or a net loss per diluted share of $1.81, for the three m, EPS a net loss per diluted share of $1.81, for the three months ended December 31, 2023... a net loss per diluted share of $.
“The Company reported a net loss of approximately $8.0 million, or a net loss per diluted share of $1.81, for the three months ended December 31, 2023, compared to a net loss of approximately $10.9 million, or a net loss per diluted share of $2.61, for the same period in 2022. For the year ended December 31, 2023, the Company reported a net loss of approximately $44.6 million, or a net loss per diluted share of $10.31, compared to a net loss of approximately $42.3 million, or a net loss per diluted share of $10.15 for the same period in 2022.”
Rachael Brake resigned as Chief Scientific Officer at Corbus Pharmaceuticals Holdings, Inc..
“On February 2, 2024, Rachael Brake, Ph.D., Chief Scientific Officer of Corbus Pharmaceuticals Holdings, Inc. (the “Company”), submitted a notice of resignation to the Company.”
Corbus Pharmaceuticals Holdings, Inc. entered into Underwriting Agreement with Jefferies LLC valued at approximately $88.5 million (effective 2024-01-31).
“On January 31, 2024, Corbus Pharmaceuticals Holdings, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Jefferies LLC (the “Representative”), as representative of the several underwriters named therein (the “Underwriters”), relating to an underwritten public offering (the “Offering”) of 4,325,000 shares (the “Base Shares”) of the Company’s common stock, par value $0.0001 (the “Common Stock”), at a price to the public of $19.00 per share.”
Corbus Pharmaceuticals Holdings, Inc. received a nasdaq extension granted notice regarding stockholders equity (rules 5550(b)(1)).
“the minimum stockholders’ equity requirement for continued listing on The Nasdaq Capital Market, under Listing Rule 5550(b)(1), because the Company’s stockholders’ equity of $311,016, as reported in the Company’s Quarterly Report on Form 10-Q for the period ended September 30, 2023, was below the required minimum of $2.5 million, and because, as of November 9,”
Corbus Pharmaceuticals Holdings, Inc. received a nasdaq deficiency notice notice regarding stockholders equity (rules 5550(b)(1)).
“November 10, 2023, Corbus Pharmaceuticals Holdings, Inc. (the “Company”) received a letter (the “Letter”) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) indicating that the Company was not in compliance with the minimum stockholders’ equity requirement for continued listing on The Nasdaq Capital Market, under Listing Rule 5550(b)(1), because the Company’s stockholders’ equity of $311,016, as reported in the Company’s Quarterly Report on Form 10-Q for the period ended September 30, 2023, was below the required minimum of $2.5 million, and because, as of Nov”
Corbus Pharmaceuticals Holdings, Inc. reported financial results for the third quarter of 2023.
“today provided a corporate update and reported financial results for the third quarter of 2023.”
Corbus Pharmaceuticals Holdings, Inc. reported the three months ended June 30, 2023 results: net income net loss of approximately $8.8 million, or a net loss per diluted share of $2.05, EPS $2.05.
“The Company reported a net loss of approximately $8.8 million, or a net loss per diluted share of $2.05, for the three months ended June 30, 2023”
Corbus Pharmaceuticals Holdings, Inc. shareholders approved Advisory vote on the compensation of the Company's named executive officers at the 2023-05-18 meeting.
“The votes were cast as follows with respect to the proposal to vote, on an advisory basis, on the compensation of the Company's named executive officers as described in the Company's definitive proxy statement: Votes For Votes Against Abstentions Broker Non-Votes 244,160 60,487 9,370 1,633,476”
Corbus Pharmaceuticals Holdings, Inc. shareholders approved Ratification of the appointment of EisnerAmper LLP as the Company's independent registered public accounting firm for the Company's fiscal year ending December 31, 2023 at the 2023-05-18 meeting.
“The proposal to ratify the appointment of EisnerAmper LLP as the Company's independent registered public accounting firm for the Company's fiscal year ending December 31, 2023 was approved based upon the following votes: Votes For Votes Against Abstentions 1,806,011 126,343 15,139”
Corbus Pharmaceuticals Holdings, Inc. shareholders approved Election of directors at the 2023-05-18 meeting.
“The election of each of Yuval Cohen, Alan Holmer, Avery W. Catlin, Peter Salzmann, John Jenkins, Rachelle Jacques, Anne Altmeyer, and Yong Ben as directors to hold office for a term of one year, until his or her successor is duly elected and qualified or he or she is otherwise unable to complete his or her term. The votes were cast for this matter as follows: Nominees Votes For Votes Withheld Broker Non-Votes Yuval Cohen 273,627 40,390 1,633,476 Alan Holmer 277,778 36,239 1,633,476 Avery W. Catlin 279,436 34,581 1,633,476 Rachelle Jacques 258,401 55,616 1,633,476 John Jenkins 280,600 33,417 1,633,476 Peter Salzmann 278,204 35,813 1,633,476 Anne Altmeyer 280,813 33,204 1,633,476 Yong Ben 281,040 32,977 1,633,476”
Corbus Pharmaceuticals Holdings, Inc. reported the three months ended March 31, 2023 results: net income a net loss of approximately $17.7 million, or a net loss per diluted share of $4.24, EPS a net loss per diluted share of $4.24.
“The Company reported a net loss of approximately $17.7 million, or a net loss per diluted share of $4.24, for the three months ended March 31, 2023”
Craig Millian resigned as Chief Operating Officer at Corbus Pharmaceuticals Holdings, Inc..
“On April 24, 2023, Mr. Millian and the Company entered into a Separation and General Release Agreement (the “Separation Agreement”) related to Mr. Millian’s resignation as Chief Operating Officer from the Company.”
Corbus Pharmaceuticals Holdings, Inc. reported the year ended December 31, 2022 results: net income a net loss of approximately $42.3 million, EPS a net loss per diluted share of $10.15.
“For the year ended December 31, 2022, the Company reported a net loss of approximately $42.3 million, or a net loss per diluted share of $10.15”
Corbus Pharmaceuticals Holdings, Inc. reported the three months ended December 31, 2022 results: net income a net loss of approximately $10.9 million, EPS a net loss per diluted share of $2.61.
“The Company reported a net loss of approximately $10.9 million, or a net loss per diluted share of $2.61, for the three months ended December 31, 2022”
Craig Millian resigned as Chief Operating Officer at Corbus Pharmaceuticals Holdings, Inc..
“On March 3, 2023, Craig Millian, Chief Operating Officer of the Company, submitted a notice of resignation to the Company to pursue other opportunities.”
Yong Ben was appointed as member of the Board at Corbus Pharmaceuticals Holdings, Inc..
“On March 1, 2023, the Board of Directors (the “Board”) of Corbus Pharmaceuticals Holdings, Inc. (the “Company”), upon the recommendation of the Nominating and Corporate Governance Committee of the Board, appointed Yong Ben, M.D., MBA, age 49, to serve as a member of the Board.”
Corbus Pharmaceuticals Holdings, Inc.: Amendment to Certificate of Incorporation to effect a 1-for-30 reverse stock split (effective 2023-02-14).
“On February 9, 2023, the Board approved a 1-for-30 Reverse Stock Split (“Reverse Stock Split”) and the Company filed the Amendment for the Reverse Stock Split with the Secretary of State of the State of Delaware. The Reverse Stock Split will become effective in accordance with the terms of the Amendment at 12:01 AM Eastern Time on February 14, 2023 (the “Effective Time”).”
Corbus Pharmaceuticals Holdings, Inc. entered into Exclusive License Agreement with CSPC Megalith Biopharmaceutical Co., Ltd. valued at $7.5 million (effective 2023-02-12).
“On February 12, 2023, Corbus Pharmaceuticals Holdings, Inc. (the “Company”) entered into an Exclusive License Agreement (the “License Agreement”) with CSPC Megalith Biopharmaceutical Co., Ltd. (“CSPC”), pursuant to which the Company received an exclusive license to obtain certain exclusive rights to develop and commercialize CRB-701 (SYS6002), a novel clinical stage antibody drug conjugate targeting Nectin-4.”
Corbus Pharmaceuticals Holdings, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2)).
“January 4, 2023, Corbus Pharmaceuticals Holdings, Inc. (the “Company”) received a letter from the Listing Qualifications Staff (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) indicating that, based upon the Company’s continued non-compliance with the minimum bid price requirement in Nasdaq Listing Rule 5550(a)(2) (the “Minimum Bid Price Requirement”) for continued listing on The Nasdaq Capital Market, the Staff had determined to delist the Company’s securities from Nasdaq unless the Company timely requests a hearing before the Nasdaq Hearings Panel (the “Panel”). The Company intends to”
Corbus Pharmaceuticals Holdings, Inc. reported the three months ended September 30, 2022 results: net income net loss of approximately $8.8 million, EPS net loss per diluted share of $0.07.
“The Company reported a net loss of approximately $8.8 million, or a net loss per diluted share of $0.07, for the three months ended September 30, 2022”
Corbus Pharmaceuticals Holdings, Inc. shareholders approved Approval of the adjournment of the Special Meeting to the extent there are insufficient votes to approve the Reverse Stock Split Proposal at the 2022-12-20 meeting.
“2. The Adjournment Proposal. The votes were cast for this matter as follows: Votes For Votes Against Abstentions 51,281,428 10,784,629 603,069”
Corbus Pharmaceuticals Holdings, Inc. shareholders approved Adoption and approval of an amendment to the Company’s Amended and Restated Certificate of Incorporation to effect a reverse stock split of common stock at a ratio from 1:4 to 1:40 at the 2022-12-20 meeting.
“1. The Reverse Stock Split Proposal. The votes were cast for this matter as follows: Votes For Votes Against Abstentions 25,794,110,289,993 5,064,240,621,803 474,524,757,330”
Corbus Pharmaceuticals Holdings, Inc. amended Amended Loan Agreement with K2 HealthVentures LLC, as administrative agent, and the lenders party thereto (effective 2022-10-25).
“On October 25, 2022, Corbus Pharmaceuticals Holdings, Inc. (the “ Company ”) entered into an amendment to the Loan and Security Agreement (the “ Loan Agreement ” and the amendment, the “ Amended Loan Agreement ”), dated as of July 28, 2020, with its subsidiary, Corbus Pharmaceuticals, Inc. as borrower, the Company as guarantor, each lender party thereto (the “ Lenders ”), K2 HealthVentures LLC, as administrative agent for the Lenders, and Ankura Trust Company, LLC, as collateral agent for the Lenders.”
Anne Altmeyer was appointed as Director at Corbus Pharmaceuticals Holdings, Inc..
“appointed Anne Altmeyer, Ph.D., MBA, MPH, age 58, to serve as a member of the Board.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.